- Home
- NPCE vs ZURA Comparison
NPCE vs ZURA Comparison
Compare NPCE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | ZURA |
|---|---|---|
| Founded | 1997 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.6M | 435.0M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NPCE | ZURA |
|---|---|---|
| Price | $14.03 | $6.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $18.33 | $11.78 |
| AVG Volume (30 Days) | 171.7K | ★ 482.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,986,000.00 | N/A |
| Revenue This Year | $25.95 | N/A |
| Revenue Next Year | $0.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.13 | N/A |
| 52 Week Low | $7.56 | $0.99 |
| 52 Week High | $18.97 | $7.19 |
Technical Indicators
Market Signals| Indicator | NPCE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 60.94 |
| Support Level | $9.52 | $5.62 |
| Resistance Level | $16.96 | N/A |
| Average True Range (ATR) | 0.83 | 0.50 |
| MACD | -0.05 | -0.00 |
| Stochastic Oscillator | 50.16 | 80.14 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.